328 related articles for article (PubMed ID: 33912187)
21. T cell receptor β-chain repertoire analysis of tumor-infiltrating lymphocytes in pancreatic cancer.
Cui C; Tian X; Wu J; Zhang C; Tan Q; Guan X; Dong B; Zhao M; Lu Z; Hao C
Cancer Sci; 2019 Jan; 110(1):61-71. PubMed ID: 30426614
[TBL] [Abstract][Full Text] [Related]
22. T-cell receptor Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia.
de Vries AC; Langerak AW; Verhaaf B; Niemeyer CM; Stary J; Schmiegelow K; van Wering ER; Zwaan CM; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
Leukemia; 2008 Jun; 22(6):1170-4. PubMed ID: 18323803
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the Repertoire Features of TCR Beta Chain CDR3 in Human by High-Throughput Sequencing.
Hou X; Wang M; Lu C; Xie Q; Cui G; Chen J; Du Y; Dai Y; Diao H
Cell Physiol Biochem; 2016; 39(2):651-67. PubMed ID: 27442436
[TBL] [Abstract][Full Text] [Related]
24. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
[TBL] [Abstract][Full Text] [Related]
25. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
[TBL] [Abstract][Full Text] [Related]
26. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X
Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the CDR3 length repertoire and the diversity of T cell receptor α and β chains in swine CD4+ and CD8+ T lymphocytes.
Wang CY; Fang YX; Chen GH; Jia HJ; Zeng S; He XB; Feng Y; Li SJ; Jin QW; Cheng WY; Jing ZZ
Mol Med Rep; 2017 Jul; 16(1):75-86. PubMed ID: 28534993
[TBL] [Abstract][Full Text] [Related]
28. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
29. Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses.
O'Keefe CL; Plasilova M; Wlodarski M; Risitano AM; Rodriguez AR; Howe E; Young NS; Hsi E; Maciejewski JP
J Immunol; 2004 Feb; 172(3):1960-9. PubMed ID: 14734782
[TBL] [Abstract][Full Text] [Related]
30. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
[TBL] [Abstract][Full Text] [Related]
31. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Ishikawa T
Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411
[TBL] [Abstract][Full Text] [Related]
32. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis.
Zeidan AM; Zhu W; Stahl M; Wang R; Huntington SF; Giri S; Podoltsev NA; Gore SD; Ma X; Davidoff AJ
Leuk Lymphoma; 2019 Dec; 60(13):3181-3187. PubMed ID: 31170846
[TBL] [Abstract][Full Text] [Related]
33. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia.
Matsutani T; Yoshioka T; Tsuruta Y; Shimamoto T; Ohyashiki JH; Suzuki R; Ohyashiki K
Leuk Res; 2003 Apr; 27(4):305-12. PubMed ID: 12531221
[TBL] [Abstract][Full Text] [Related]
34. Shorter TCR β-Chains Are Highly Enriched During Thymic Selection and Antigen-Driven Selection.
Hou X; Zeng P; Zhang X; Chen J; Liang Y; Yang J; Yang Y; Liu X; Diao H
Front Immunol; 2019; 10():299. PubMed ID: 30863407
[TBL] [Abstract][Full Text] [Related]
35. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.
Sloand EM; Mainwaring L; Fuhrer M; Ramkissoon S; Risitano AM; Keyvanafar K; Lu J; Basu A; Barrett AJ; Young NS
Blood; 2005 Aug; 106(3):841-51. PubMed ID: 15827127
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
37. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
Sekeres MA
Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
[TBL] [Abstract][Full Text] [Related]
38. Next-generation sequencing analysis of the human T-cell and B-cell receptor repertoire diversity before and after hepatitis B vaccination.
Miyasaka A; Yoshida Y; Wang T; Takikawa Y
Hum Vaccin Immunother; 2019; 15(11):2738-2753. PubMed ID: 30945971
[TBL] [Abstract][Full Text] [Related]
39. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of T-cell receptor repertoires reveals antigen-driven T-cell clusters in patients with Behçet's syndrome.
Zou J; Li B; Li D; Bao HF; She CH; Ye JF; Cai JF; Guan JL
Eur J Immunol; 2023 Apr; 53(4):e2250181. PubMed ID: 36747316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
